|
1
|
World health Organization Classification
of Tumors of the Digesive System. IARC Press; Lyon: 2012
|
|
2
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Higuchi R, Ota T, Araida T, Kobayashi M,
Furukawa T and Yamamoto M: Prognostic relevance of ductal margins
in operative resection of bile duct cancer. Surgery. 148:7–14.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagino M, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Takahashi Y and Nimura Y: Evolution of surgical
treatment for perihilar cholangiocarcinoma: A single-center 34-year
review of 574 consecutive resections. Ann Surg. 258:129–140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Furukawa T, Hatori T, Fujita I, Yamamoto
M, Kobayashi M, Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, et
al: Prognostic relevance of morphological types of intraductal
papillary mucinous neoplasms of the pancreas. Gut. 60:509–516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toba T, Kijima H, Hakamada K and Igarashi
Y: Histological phenotype is correlated with the wall-invasion
pattern of gallbladder adenocarcinoma. Biomed Res. 35:295–302.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan
YY, Yeh TS, Chiu CT, Kuo TT, Kamiya J, Oda K, et al: Intraductal
papillary neoplasia of the liver associated with hepatolithiasis.
Hepatology. 34:651–658. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki Y, Atomi Y, Sugiyama M, Isaji S,
Inui K, Kimura W, Sunamura M, Furukawa T, Yanagisawa A, Ariyama J,
et al: Cystic neoplasm of the pancreas: A Japanese
multiinstitutional study of intraductal papillary mucinous tumor
and mucinous cystic tumor. Pancreas. 28:241–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furukawa T, Klöppel G, Adsay N Volkan,
Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y,
Klimstra DS, Longnecker DS, et al: Classification of types of
intraductal papillary-mucinous neoplasm of the pancreas: A
consensus study. Virchows Arch. 447:794–799. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Surgery JSoB: Classification of biliary
tract carcinoma. 2nd. Kanehara and Co., Ltd.; Tokyo: 2004
|
|
11
|
Albores-Saavedra J, Adsay NV, Crawford JM,
Klimstra DS and Kloppel G: World health organization of
classification of tumors of the digestive system. IARC; Lyon:
2010
|
|
12
|
Sobin LH, Gospodarowicz MK and Wittekind
CH: TNM Classification of Malignant Tumours (UICC). 7th.
Wiler-Liss; New York: 2009
|
|
13
|
Yamamoto M, Nakajo S and Tahara E:
Carcinoma of the gallbladder: The correlation between histogenesis
and prognosis. Virchows Arch A Pathol Anat Histopathol. 414:83–90.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haga T, Yoshizawa T, Morohashi S, Hirai H,
Saitou K, Ota R, Takatsuna A, Wu Y, Fukuda S and Kijima H:
Phenotypic characterization of early biliarytract carcinomas
proposes two carcinogenesis pathways. Hirosaki Med J. 67:28–38.
2016.
|
|
15
|
Sawada T, Ho JJ, Chung YS, Sowa M and Kim
YS: E-selectin binding by pancreatic tumor cells is inhibited by
cancer sera. Int J Cancer. 57:901–907. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wesseling J, van der Valk SW, Vos HL,
Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression
inhibits integrin-mediated cell adhesion to extracellular matrix
components. J Cell Biol. 129:255–265. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hudson MJ, Stamp GW, Chaudhary KS, Hewitt
R, Stubbs AP, Abel PD and Lalani EN: Human MUC1 mucin: A potent
glandular morphogen. J Pathol. 194:373–383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu F, Liu F, Zhao H, An G and Feng G:
Prognostic significance of mucin antigen MUC1 in various human
epithelial cancers: A meta-analysis. Medicine (Baltimore).
94:e22862015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campos LC, Silva JO, Santos FS, Araújo MR,
Lavalle GE, Ferreira E and Cassali GD: Prognostic significance of
tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet
Diagn Invest. 27:531–535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Hu YM, Du YJ, Zhu LR, Qian H, Wu Y
and Shi WL: Expressions of MUC1 and vascular endothelial growth
factor mRNA in blood are biomarkers for predicting efficacy of
gefitinib treatment in non-small cell lung cancer. Bmc Cancer.
14:8482014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jerome KR, Barnd DL, Bendt KM, Boyer CM,
Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr and Finn OJ:
Cytotoxic T-lymphocytes derived from patients with breast
adenocarcinoma recognize an epitope present on the protein core of
a mucin molecule preferentially expressed by malignant cells.
Cancer Res. 51:2908–2916. 1991.PubMed/NCBI
|
|
22
|
Kontani K, Taguchi O, Narita T, Izawa M,
Hiraiwa N, Zenita K, Takeuchi T, Murai H, Miura S and Kannagi R:
Modulation of MUC1 mucin as an escape mechanism of breast cancer
cells from autologous cytotoxic T-lymphocytes. Br J Cancer.
84:1258–1264. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato Y: Efficacy of WT1 peptide-/MUC-1
peptide-pulsed dendritic cell therapy in 313 patients with a wide
range of cancers. Gan To Kagaku Ryoho. 41:1280–1282. 2014.(In
Japanese). PubMed/NCBI
|
|
24
|
Park SY, Roh SJ, Kim YN, Kim SZ, Park HS,
Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of MUC1,
MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact.
Oncol Rep. 22:649–657. 2009.PubMed/NCBI
|
